Hot Spot Pollutants Pharmaceuticals in the Environment 1st Edition by Daniel R Dietrich, Simon Webb, Thomas Petry ISBN 0120329530 9780120329533

Hot Spot Pollutants Pharmaceuticals in the Environment 1st Edition by Daniel R Dietrich, Simon Webb, Thomas Petry – Ebook PDF Instant Download/Delivery: 0120329530, 9780120329533
Full download Hot Spot Pollutants Pharmaceuticals in the Environment 1st Edition after payment

Product details:

ISBN 10: 0120329530 
ISBN 13: 9780120329533
Author: Daniel R Dietrich, Simon Webb, Thomas Petry

Hot Spot Pollutants describes how pharmaceuticals and/or endocrine active compounds gain entry into the aquatic ecosystem, effects on specific organisms and the potential risk involved for the whole ecosystem. In addition it presents the latest views and developments regarding legal requirements for assessing the environmental risk of pharmaceuticals. This books includes the views of academic, industry and government scientists, and thus aims for a balanced presentation of all standpoints.
The book consists of papers that appeared previously in the journal Toxicology Letters in 2002 and 2003, and have been collected in this single volume to make them accessible to a broader audience. Authors were asked to update their contributions where necessary. See also Toxicology Letters volume 131, issues 1 and 2 (2002), and volume 142 issue 3 (2003).

Hot Spot Pollutants Pharmaceuticals in the Environment 1st Table of contents:

Part I: Editorial
Chapter 1. Hot Spot Pollutants: Pharmaceuticals in the Environment
Text
References
Part II: Occurrence and Fate
Chapter 2. Occurrence, Fate, and Removal of Pharmaceutical Residues in the Aquatic Environment: An E
I. Introduction and Background
II. Occurrence of PhACs in Sewage, Surface, Ground, and Drinking Water
III. Conclusions
References
Chapter 3. The Sorption and Transport of a Sulphonamide Antibiotic in Soil Systems
I. Introduction
II. Methods
III. Results
IV. Discussion
V. Conclusions
References
Chapter 4. Concentrations of the UV Filter Ethylhexyl Methoxycinnamate in the Aquatic Compartment: A
I. Introduction
II. Methods
III. Results
IV. Discussion
References
Chapter 5. Exposure Simulation for Pharmaceuticals in European Surface Waters with GREAT-ER
I. Introduction
II. GREAT-ER System Description
III. Output of GREAT-ER
IV. Methods
V. Results and Discussion
VI. Conclusions
References
Chapter 6. Indirect Human Exposure to Pharmaceuticals via Drinking Water
I. Introduction
II. Methodology
III. Results
IV. Discussion
V. Conclusions
References
Part III: Effects
Chapter 7. Morphological Sex Reversal Upon Short-Term Exposure to Endocrine Modulators in Juvenile F
I. Introduction
II. Materials and Methods
III. Results
IV. Discussion
References
Chapter 8. Determination of Vitellogenin Kinetics in Male Fathead Minnows (Pimephales promelas)
I. Introduction
II. Materials and Methods
III. Results
IV. Discussion
References
Chapter 9. Integrated In Vivo and In Vitro Assessment of Reproductive and Developmental Effects of E
I. Introduction
II. Invertebrate Diversity
III. Ecotoxicity Testing with Crustaceans and Insects
IV. Conclusions and Recommendations
References
Chapter 10. How Can Toxic Effects of Pollution of the Aquatic Environment on the Immunocompetence of
I. Introduction
II. Evaluation of Natural Resistance or Immunity Against Bacterial and Viral Infection
III. Activation of Leukocytes and Leukocyte Subpopulations
IV. Phagocytosis
V. Respiratory Burst
VI. Antibody Secretion
VII. Specific Cell-Mediated Cytotoxicity
VIII. Gene Array
IX. Discussion
References
Chapter 11. Aquatic Ecotoxicology of Fluoxetine: A Review of Recent Research
I. Introduction
II. Fluoxetine Exposure and Detection in Surface Waters
III. Single Species Toxicity Test Organism Responses to Fluoxetine
IV. Medaka Reproduction and Endocrine Function Responses to Fluoxetine
V. Fluoxetine Effects: Community Responses to Fluoxetine, Ibuprofen, and Ciprofloxacin Mixtures
VI. Ecological Risk Characterization for Fluoxetine
VII. Conclusions
References
Chapter 12. Aquatic Ecotoxicity of Pharmaceuticals Including the Assessment of Combination Effects
I. Introduction
II. Methods
III. Results
IV. Discussion
V. Conclusions
References
Part IV: Principal Considerations
Chapter 13. Environmental Risk Assessment of Pharmaceutical Drug Substances„Conceptual Considerati
I. Introduction
II. Available Relevant Pharmacological, Pharmacodynamic, and Toxicological Information
III. Use of Pharmacodynamic Information from Mammalian Species in Ecotoxicological Test Strategies
IV. Use of Pharmacological and Toxicological Information from Mammalian Species in Ecotoxicological
V. Use of Pharmacokinetic Information in Ecotoxicological Test Strategies
VI. Criteria for the Development of an Ecotoxicological Test Strategy
VII. Conclusions and Recommendations
References
Chapter 14. Pharmacodynamic Activity of Drugs and Ecotoxicology„Can the Two Be Connected?
I. Introduction
II. Problem Statement
III. Mammalian Pharmacodynamics and Ecospecies
IV. Ecotoxicology vs. Mammalian (Human) Toxicology
V. Conclusion
References
Chapter 15. Proposed Development of Sediment Quality Guidelines Under the European Water Framework D
I. Introduction
II. Water Framework Directive
III. Outstanding Questions on European Union Sediment EQSs
IV. Conclusions
References
Part V: Risk Assessment
Chapter 16. Prioritization of Veterinary Medicines in the UK Environment
I. Introduction
II. Prioritization Approach
III. Results
IV. Discussion
V. Conclusions
References
Chapter 17. European Medicines and Feed Additives Regulation Are Not in Compliance With Environmenta
I. Introduction
II. EU Environmental Legislation and the Relation to Product Registration
III. Product Registration and the Relation with EU Environmental Policy and Laws
IV. Product Directives on Medicines and the Environmental Assessment
V. The Development of the ERA for Veterinary Medicinal Products in Europe
VI. Contents of the ERA for Veterinary Medicines
VII. Implementation of the ERA
VIII. Discussion and Conclusions
References
Chapter 18. Environmental Risk Assessment of Veterinary Pharmaceuticals in the EU: Reply to Montfort
I. Introduction
II. Marketing Authorization for VMPs in the European Union
III. The VICH Process
IV. VICH Phase I Guidance on Ecotoxicity
V. VICH Phase II Guidance
VI. Conclusions
References
Chapter 19. Environmental Risk Assessment for New Human Pharmaceuticals in the European Union Accord
I. Introduction
II. General Principles of the 2003 Human Pharmaceuticals ERA Draft Guideline
III. Discussion

People also search for Hot Spot Pollutants Pharmaceuticals in the Environment 1st:

    
pollution hot spot
    
hot spot analysis air quality
    
pollution hot spot example
    
air pollution hot spots
    
a pollutant is

Tags: Daniel R Dietrich, Simon Webb, Thomas Petry, Pollutants Pharmaceuticals, Environment